Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

NCT00904397 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

98

Enrollment

INDUSTRY

Sponsor class

Stopped Rofecoxib was withdrawn from the market due to safety concerns.

Conditions

Chronic Low Back Pain

Interventions

DRUG: Lidoderm®
DRUG: Celecoxib

Sponsor

Endo Pharmaceuticals